Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2003 Jul 16;23(15):6385–6391. doi: 10.1523/JNEUROSCI.23-15-06385.2003

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2003 Society for Neuroscience 0270-6474/03/236385-07.00/0

PMC Copyright notice

Figure 2. — Group data (means and SE) in rabbits showing the effect of intravenous MDMA and then clozapine (1 and 5 mg/kg) or olanzapine on body temperature (A) and ear pinna blood flow (B). Data points at time 0 are means and SE of the preinjection control period. Two rabbits in the MDMA-no treatment group were killed 45 min after MDMA. Numbers of rabbits: see Results for number of rabbits in MDMA-no treatment group; n = 7 for clozapine 1 mg/kg; n = 5 for clozapine 5 mg/kg; n = 6 for olanzapine 0.5 mg/kg. Symbols for analysis by repeated measures ANOVA and Fisher's PLSD comparison in A: ^##significantly greater than pre-MDMA control temperature value (no treatment group, F_(12,144) = 77.44; p < 0.0001; clozapine 1 mg/kg group, F_(12,60) = 17.61; p < 0.001; clozapine 5 mg/kg group F_(12,48) = 3.68; p < 0.01; olanzapine group, F_(12,60) = 33.48; p < 0.001); ^**significantly greater than pre-MDMA control value (F values as above; p < 0.0001 for no treatment group; p < 0.001 for clozapine 1 mg/kg group); ^••significantly <30 min post-MDMA value (F values as above; p < 0.001 for clozapine 5 mg/kg group; p < 0.0001 for olanzapine group); ns, not significantly different from pre-MDMA control value (F values as above; p > 0.05 for clozapine 5 mg/kg group; p > 0.05 for olanzapine group). Symbols for analysis by factorial ANOVA and Fisher's PLSD comparison in A: ^††significantly <60 min post-MDMA temperature in MDMA-no treatment rabbits (F_(3,26) = 17.503; clozapine 1 mg/kg group, p < 0.001; clozapine 5 mg/kg group, p < 0.0001; olanzapine group p < 0.0001). Symbols for analysis by repeated measures ANOVA and Fisher's PLSD comparison in B: ^##significantly less than pre-MDMA ear pinna blood flow control value (no treatment group, F_(12,144) = 28.26; p < 0.0001; clozapine 1 mg/kg group, F_(12,72) = 13.28; p < 0.0001; clozapine 5 mg/kg group, F_(12,48) = 18.29; p < 0.0001; olanzapine group, F_(12,60) = 14.57; p < 0.0001); ^**significantly less than pre-MDMA control value (F values as above; p < 0.0001 for no treatment group; p < 0.0001 for olanzapine group); ^§§significantly greater than pre-MDMA control value (F values as above; p < 0.01); ^••significantly >15 min post-MDMA value (F values as above; p < 0.0001 for clozapine 5 mg/kg group; p < 0.0001 for clozapine 1 mg/kg group; p < 0.01 for olanzapine group); ns, not significantly different from pre-MDMA control value (F values as above; p > 0.05 for clozapine 1 mg/kg group; p > 0.05 for olanzapine group). Symbols for analysis by factorial ANOVA and Fisher's PLSD comparison in B: ^††significantly >60 min post-MDMA ear pinna blood flow in MDMA-no treatment rabbits (F_(3,26) = 17.503; clozapine 5 mg/kg group, p < 0.0001; clozapine 1 mg/kg group, p < 0.001; olanzapine group, p < 0.0001).